Yi Tong1†
Zheng Zuo1†
Xinqi Li2†Minghua Li1Zhenggui Wang1Xiaoxue Guo1Xishu Wang1Ying Sun1Dongmei Chen1*
Zhiguo Zhang1*- 1Center for Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, China
- 2Center for Cardiovascular Medicine, The Second Hospital of Jilin University, Changchun, China
This review provides an overview of the key role played by perivascular adipose tissue (PVAT) in the protection of cardiovascular health. PVAT is a specific type of adipose tissue that wraps around blood vessels and has recently emerged as a critical factor for maintenance of vascular health. Through a profound exploration of existing research, this review sheds light on the intricate structural composition and cellular origins of PVAT, with a particular emphasis on combining its regulatory functions for vascular tone, inflammation, oxidative stress, and endothelial function. The review then delves into the intricate mechanisms by which PVAT exerts its protective effects, including the secretion of diverse adipokines and manipulation of the renin-angiotensin complex. The review further examines the alterations in PVAT function and phenotype observed in several cardiovascular diseases, including atherosclerosis, hypertension, and heart failure. Recognizing the complex interactions of PVAT with the cardiovascular system is critical for pursuing breakthrough therapeutic strategies that can target cardiovascular disease. Therefore, this review aims to augment present understanding of the protective role of PVAT in cardiovascular health, with a special emphasis on elucidating potential mechanisms and paving the way for future research directions in this evolving field.
1 Introduction
Cardiovascular disease is a major cause of illness and death worldwide, through its effects on the heart and blood vessels (1, 2). This collective name covers a variety of diseases, including coronary heart disease, heart failure, and stroke. Despite advances in medical treatments, cardiovascular disease continues to pose significant burdens on both healthcare systems and individuals. In general, perivascular adipose tissue (PVAT) encircles nearly all blood vessels other than those supplying the nerves and pulmonary vasculature (3–6). Traditionally, PVAT has been considered an inert connective tissue that provides structural support to these vessels. However, emerging evidence has revealed that PVAT is not a passive bystander but instead has an active role in cardiovascular disease (7, 8). In this review, we initially summarize the recent research findings and advances related to the cellular origin and organization of PVAT, then discuss the anti-inflammatory, vasodilatory, and anti-constrictive actions of PVAT, and finally examine the potential of PVAT as a future therapeutic target for cardiovascular disease.
2 Cellular origin and structure of PVAT
2.1 Cellular origin
The complex cellular components of PVAT include various cell types, notably adipocytes, fibroblasts, immune cells, and vascular cells (9, 10). Adipocytes have a central role in PVAT as the primary cells responsible for producing and releasing adipokines, cytokines, and other biologically active molecules (11). Regarding the other cell types, fibroblasts facilitate reshaping of the extracellular matrix to maintain the structural integrity of PVAT (12), immune cells (macrophages, T cells) actively participate in the inflammatory and immune responses of PVAT (13, 14), and vascular cells (smooth muscle cells [SMCs], endothelial cells [ECs]) have an underlying involvement in the vascular function of PVAT (15). Research has indicated that PVAT also contains adipocytes derived from mesenchymal precursors known as SM22α+ cells, which are commonly found around the aorta and act as an important source of vascular smooth muscle cells (VSMCs) (16). Other studies have demonstrated that adipose-derived stem cells from percutaneous and visceral adipose tissue can differentiate into various types of vascular cells, including ECs and SMCs (12, 17).
Despite the growing interest in PVAT, the origins of its cellular components have not been fully elucidated. PVAT cells are hypothesized to arise from a variety of sources, including resident progenitor cells in adipose tissue and cells migrating from other tissues (15). Research has shown that adipocyte progenitor cells, also known as preadipocytes, can differentiate into mature adipocytes and contribute to the expansion of PVAT (18). Moreover, recent evidence has suggested that cells from the vascular adventitia, such as pericytes and mesenchymal stem cells, can differentiate into PVAT cells under specific conditions (19).
2.2 Tissue structure
Blood vessels have three distinct layers: the intima, media, and adventitia layers. The intima layer primarily consists of ECs, while the media layer is predominantly composed of SMCs. The adventitia layer, which contains nerve endings, can be further categorized into two sublayers: the adventitial compacta and adventitial fat (20). The adventitial compacta primarily contains fibroblasts, while the adventitial fat mainly consists of adipocytes. The terms perivascular fat and PVAT are often used interchangeably with adventitial fat (21).
Regarding adipose tissue itself, there are typically three different types: white adipose tissue (WAT), brown adipose tissue (BAT), and beige adipose tissue (BeAT). Similar to other adipose tissue depots, PVAT is a combination of WAT and BAT, with varying proportions depending on the organs involved (22). Development of brown and white adipocytes is associated with distinct lineages, although there is some overlap, and their exact origins remain uncertain. Thus, further investigations are required to fully understand the regulatory mechanisms and developmental origins of these adipocytes.
WAT is primarily composed of white adipocytes that house singular, sizable lipid droplets, and it is mainly situated in the hypodermis and perivisceral region. It specializes in storing and mobilizing fat, and its metabolic pathways modulate the production of proteins and lipids, which can have significant effects on inflammation and insulin sensitivity both locally and systemically (23).
On the contrary, BAT, which is transiently present in the interscapular and mediastinal regions of humans, has distinctive thermogenic properties and functions in maintaining a stable body temperature. Furthermore, brown-like adipocytes, which are rich in lipid droplets and mitochondria, can regulate body temperature by generating calories through lipid metabolism (24). By employing 18F-FDG PET-CT imaging, it has been discovered that functional BAT is prevalent in adults and consumes a substantial amount of energy. Therefore, methods that can increase the volume or activity of BAT have potential as treatments for metabolic diseases (25).
A comprehensive examination of human coronary arteries indicated that PVAT expresses certain genes at intermediate levels between WAT and BAT (26). Understanding the origins and developmental pathways of thermogenic PVAT adipocytes in adults is crucial for the development of therapeutic approaches that can enhance BAT accumulation (9). Notably, PVAT in various parts of the body shows similarities to different types of adipose tissue. The phenotype of PVAT is influenced by its location, with thoracic and abdominal PVAT exhibiting distinct characteristics. Specifically, abdominal PVAT has similarities to WAT, while thoracic PVAT shares more traits with BAT (27–29). Consistent with this, human aortic and coronary PVAT showed similarities with BAT in terms of the expression of BeAT (30). Because mitochondria contain large amounts of UCP1 protein, both BAT and BeAT are thermogenic. Unlike WAT, BAT and BeAT have anti-inflammatory properties, and thus we focused on the cellular origin of thoracic aortic PVAT to examine whether it exerts anti-inflammatory effects.
To determine the proteomic similarities, a comprehensive proteomic analysis was performed on PVAT, BAT, and WAT in ApoE−/− mice, and a principal component analysis of the proteomic profiles revealed common protein expression patterns in PVAT and BAT that distinguished them from WAT (16). Furthermore, the proteomic features of PVAT resembled those of BAT (16). Thoracic PVAT was more similar to traditional BAT than to BeAT from a morphologic and structural point of view. Analyses of the global gene expression profiles using DNA microarrays revealed that PVAT had almost identical gene expression profiles to BAT, with Ucp1, Cidea, and other genes uniquely expressed or highly overexpressed in BAT with similar levels of expression (31, 32).
From a functional standpoint, PVAT plays a crucial role in the regulation of intravascular temperature, similar to BAT. In addition, PVAT exhibits thermogenic properties upon exposure to cold temperatures. In SMPG KO model mice with VSMCs that were rendered deficient in the adipogenic transcription factor peroxisome proliferator-activated receptor-γ (PPARγ) using a SM22α-Cre knock-in strategy (33), the absence of PVAT led to impaired thermogenic activity, resulting in decreased temperature and endothelial dysfunction (34). Notably, the SMPG KO mice had no PVAT due to the absence of PPARγ, resulting in a lack of PVAT surrounding vessels like the thoracic and abdominal aorta. This lack of PVAT further contributed to the decrease in intravascular temperature. In mammals, variations in ambient temperature elicit a vascular reaction that involves the functions of ECs and SMCs. A similar physiological mechanism may exist in humans, whereby the intravascular temperature gradient increases in large veins as blood approaches the heart (35), thus highlighting the critical role for PVAT in the maintenance of vascular homeostasis.
The structure and functionality of PVAT are also influenced by various physiological parameters, including aging, sex, and race. Mechanical considerations, such as intravascular injuries, also affect the properties of PVAT. In addition to its cellular components, PVAT includes collagens, elastic fibers, nerve fibers, capillaries, and other components (Figure 1).
Figure 1 PVAT and the architecture of the vascular wall. This figure is created with MedPeer (www.medpeer.cn).
3 Vasoprotective effects of PVAT
Under physiological conditions, PVAT has a range of beneficial effects, including anti-inflammatory properties, optimization of free fatty acid metabolism, and regulation of vasodilation (36). A major underlying mechanism for how PVAT exerts its effects is through the release of substances called adipocyte-derived relaxing factors (ADRFs), which have important roles in modulating vascular structure and function (7, 11, 37). ADRFs mostly comprise adiponectin, leptin, nitric oxide (NO), hydrogen sulfide (H2S), hydrogen peroxide (H2O2), and fibroblast growth factor-21 (FGF-21), although it was recently found that expression of the mitochondrial inner membrane protein UCP1 and depletion of dendritic cells in PVAT can also increase the anti-inflammatory effects of PVAT (32, 38). The anti-contractile and anti-inflammatory effects of PVAT are summarized in Tables 1, 2; Figure 2.
Table 1 The anti-contractile and anti-inflammatory effects of PVAT in vitro study.
Table 2 The anti-contractile and anti-inflammatory effects of PVAT in vivo study.
Figure 2 A major underlying mechanism for how PVAT exerts its effects is through the release of substances called adipocyte-derived relaxing factors (ADRFs), which have important roles in modulating vascular structure and function. Adiponectin causes vasodilation by affecting adiponectin receptors (AR) in endothelial cells, which contributes to the activation of locations 5′ adenosine monophosphate-activated protein kinase (AMPK), which is responsible for the activation of endothelial NO synthase (eNOS). Enhanced NO concentration induces activation of cyclic guanosine monophosphate (cGMP), which is responsible for opening large-conductance calcium-activated potassium channels (BKCa). eNOS is present in both endothelial cells and adipocytes. Moreover, Adiponectin directly regulates the phenotype of macrophages and facilitates their transition from the pro-inflammatory M1 macrophages to the anti-inflammatory M2 macrophages. Leptin activates leptin receptors (LR), which are responsible for activation of not only AMPK, but also endothelium-derived hyperpolarizing factor (EDHF), which activates BKCa. Moreover, AMPK independently activates BKCa and induces a hyperpolarization effect. Hydrogen sulfide (H2S) induces activation of BKCa in VSMCs and endothelial cells, and H2S can inhibit the degradation of eNOS and induce its phosphorylation, resulting in NO generation via the PI3K/Akt pathway and p38 MAPK pathway. Moreover, it induces a decrease in intracellular pH by the activation of Cl−/HCO3− ionic exchanger. Angiotensin 1–7 (Ang 1–7) by affecting endothelial Ang 1–7 receptor (MAS) activates eNOS and increases the NO concentration. Prostacyclin interacts with receptors present on blood vessels, and has an important role in vasodilatory properties. Hydrogen peroxide (H2O2) stimulates the soluble guanylyl cyclase (sGC-1), which induces vasodilation through the NO/GC-1/cGMP pathway. UCP1 inhibited the activation of Nod-like receptor family pyrin domain-containing 3(NLRP3) inflammatory and decreases the levels of pro-inflammatory factors such as IL-1β. This figure is created with MedPeer (www.medpeer.cn).
3.1 Anti-contractile effects of PVAT
3.1.1 Adiponectin
PVAT-derived adiponectin is involved in several physiological procedures and has a positive role in vascular homeostasis. In the healthy body under normal conditions, PVAT produces and releases abundant adiponectin (53). This hormone functions as a vasodilator by directly affecting ECs and VSMCs through multiple mechanisms. One way in which adiponectin promotes vasodilation is through endothelial nitric oxide synthase (eNOS) via AMPK-mediated phosphorylation (39). This leads to increased generation of NO, a potent vasodilator. Adiponectin also enhances eNOS function by stimulating the phosphorylation and boosting the generation of BH4, an essential cofactor for eNOS activity (40). Studies in mice lacking AMPKα1, a key regulator of adiponectin signaling, revealed a loss of the vasodilatory effect mediated by PVAT, indicating the importance of AMPK for this process (54). Furthermore, adiponectin was shown to suppress the proliferation of VSMCs both in vivo and in vitro through an AMPK-related signaling pathway (39). In addition, AMPKα1 knockout mice had significantly lower circulating lipocalin levels, indicating that AMPK is essential for lipocalin generation and lipocalin-mediated vasodilation (54). In summary, PVAT-derived adiponectin exerts beneficial effects on vascular function by enhancing vasodilation and inhibiting VSMC proliferation. The actions of adiponectin are mediated by AMPK-dependent pathways, highlighting the vital role of this signaling molecule in the maintenance of vascular homeostasis.
3.1.2 Leptin
Leptin is an abundant secreted adipokine that has a key role in the regulation of appetite and weight. It is also considered to act as a protective adipokine for cardiovascular function (55). The vasodilation induced by leptin occurs through both endothelium-related and independent methods, with the specific mechanisms depending on the types of blood vessel involved. In major arteries, such as the aorta, leptin enhances endothelium-dependent vasodilation by activating AMPK, a mechanism comparable to that of adiponectin. This activation leads to eNOS phosphorylation and ultimately increased vasodilation. Leptin also targets vascular ECs, impeding the contractile effects of angiotensin II by decreasing calcium release into cellular stores and stimulating VSMC proliferation (49). In smaller arteries, such as the mesenteric artery, leptin triggers an increase in the production of NO and endothelium-derived hyperpolarizing factor (EDHF), both of which contribute to endothelium-related vasodilation (50). Research has demonstrated that leptin acts as an endothelium-dependent vasodilator in coronary artery disease patients, as evidenced by its effects on saphenous and internal mammary artery vascular rings (56). Furthermore, leptin induces vasodilation in human coronary blood vessels and promotes endothelial NO production by ECs in humans (57). While the role of leptin in promoting sympathetic activity is well-established, the exact mechanism by which it counteracts the effects of the sympathetic nerve system on blood pressure remains unclear. One study discovered that leptin induces a hypotensive effect when the effects of the sympathetic nerves are eliminated (56). These hemodynamic effects of leptin coincide with the endothelium-mediated vasodilatory effects induced by the same hormone through NO or EDHF on conduit and resistance arteries, respectively (56).
3.1.3 Nitric oxide
NO is a gas that easily diffuses throughout the body. It is widely recognized to act as a vasodilator, meaning that it can widen blood vessels. NO is synthesized by three different enzymes called eNOS, inducible nitric oxide synthase (iNOS), and neuronal nitric oxide synthase (nNOS) (58). The iNOS enzyme is unique because it does not require calcium ions (Ca2+) for its activity and can be stimulated by inflammatory cytokines, indicating its potential involvement in the progression of various inflammatory diseases (59). Meanwhile, the nNOS enzyme is found in the neurons of the central and peripheral nervous systems, and acts as a neurotransmitter for the modulation of blood pressure, and the eNOS enzyme, which is mainly found in ECs, has an anti-atherosclerotic property and functions in local blood pressure control (59). Research has demonstrated that eNOS is expressed not only in ECs but also in PVAT, and that atherosclerosis, a condition characterized by reduced bioavailability of NO, is closely related to endothelial dysfunction (52, 60, 61). In this context, eNOS-derived NO was shown to possess multiple anti-atherosclerotic properties, including the ability to regulate VSMC proliferation and leukocyte adhesion, inhibit platelet aggregation, and reduce vascular inflammation (52, 59). In obese individuals, excess PVAT-derived tumor necrosis factor-α (TNF-α), along with increased expression of endothelin-1(ET-1) and endothelin ETA receptors in blood vessels, disrupts the balance of the ET-1/NO system, leading to impaired release of NO (62). This imbalance is further exacerbated by the overproduction of reactive oxygen species, leading to a loss of coupling with eNOS and reduced NO generation. In contrast, when PVAT was removed in healthy people, basal NO generation in small arteries was decreased, suggesting that PVAT contributes to vascular NO generation (62). NO exerts its vasodilatory effects by relaxing VSMCs through the cGMP-PKG cascade and/or by activating potassium channels in SMCs to induce membrane hyperpolarization (63). In addition, NO can up-regulate the synthesis of H2S, another vasodilator, by increasing the availability of its precursor as well as the expression of its synthetic enzyme cystathionine gamma lyase. This interaction between NO and H2S further enhances the vasodilatory effects in the body (64).
3.1.4 Hydrogen sulfide
H2S is a gas that is synthesized by PVAT, ECs, and VSMCs. Its role in the regulation of vascular tone is crucial. The vasodilation caused by H2S is a result of its ability to activate BK channels in VSMCs. This activating effect leads to hyperpolarization of the cytosol, which in turn inactivates voltage-gated L-type Ca2+ channels. This cascade of events ultimately leads to a decrease in the intracellular Ca2+ concentration (43). Besides its role in vasodilation, H2S was shown to reduce intracellular pH in a dose-dependent manner, thus further contributing to the vasodilation process. The underlying mechanism for these effects involves the Cl−/HCO3− ion exchanger (65). Another study indicated that there may be an interaction between NO and H2S in terms of their production and pathophysiological functions (66). In the cardiovascular and cerebrovascular systems, H2S and NO influence one another and rely on each other for the regulation of angiogenesis (67). Research has shown that H2S can inhibit the degradation of eNOS and induce its phosphorylation, resulting in NO generation via the PI3K/Akt pathway (68–70) and p38 MAPK pathway (71). H2S can also increase cGMP by inhibiting the activity of phosphodiesterase (45). These effects allow H2S to exert its important anti-vasoconstrictive actions.
3.1.5 Hydrogen peroxide
H2O2 produced by PVAT has dual effects on blood vessels, by acting as both a vasoconstrictor and a vasodilator depending on various factors. These factors include the concentration of H2O2, type of blood vessel, and contractile state of the vessel (72). In healthy individuals, the H2O2 concentration is typically non-toxic. H2O2 can permeate the cell membrane and easily diffuse into SMCs, where it stimulates soluble guanylyl cyclase (sGC-1) and acts as a receptor for NO in smooth muscle to induce vasodilation via the NO/sGC-1/cGMP pathway (42). In the obese population, the contractile response to H2O2 did not change. However, H2O2 increased COX-2 expression, which subsequently promoted arterial vasoconstriction (73). A study demonstrated that the mitochondrial electron transport chain in PVAT has a role in modulating aortic muscle contraction. This is achieved through increased production of the superoxide anion (O2−), which is subsequently converted into H2O2. In this process, H2O2 acts as an important signaling molecule to modulate the contraction of vascular smooth muscle (74). Mitochondrial decoupling and H2O2 removal increase peripheral vasoconstriction by PVAT.
3.1.6 COX-derived factors
PVAT is recognized as a source of various factors that originate from adipose tissue. These factors are generated by an enzyme called cyclooxygenase (COX) and include TXA2, prostaglandin D2, prostaglandin E2, prostaglandin F2a, prostaglandin H2, and prostaglandin I (prostacyclin) (75, 76). In particular, prostacyclin is known for its vasodilatory properties. Specifically, it interacts with receptors present on blood vessels, and has an important role in protection against endothelium dysfunction and atherosclerosis (46).
3.1.7 Angiotensin 1–7
All components of the renin–angiotensin–aldosterone system (RAAS) can be found in the aortic and mesenteric PVAT, with the exception of renin (77). The RAAS components have varying effects on vascular tone. One component, Angiotensin 1–7, is known to promote vasodilation through its interaction with the endothelium (78). On the contrary, angiotensin II, which is also produced by PVAT, induces vasoconstriction (79). Angiotensin 1–7 (Ang 1–7) by affecting endothelial Ang 1–7 receptor (MAS) activates eNOS and increases the NO concentration. This increase in NO leads to blood vessel dilation through the activation of BK channels (47).
3.2 Anti-inflammatory effects of PVAT
3.2.1 Adiponectin
Adiponectin is known for its anti-atherogenic properties (80). In human atherosclerotic plaque, the two most prominent macrophage types are inflammatory M1 macrophages and anti-inflammatory M2 macrophages (81). Adiponectin inhibits the typical pro-inflammatory activity of M1 macrophages and enhances the anti-inflammatory activity of M2 macrophages, and the expression of high levels of lipocalin potentially impedes the progression of metabolic and cardiovascular disorders by facilitating the development of an anti-inflammatory macrophage phenotype (41, 82). Macrophages can be polarized towards the M1 state by interferon-γ and TNF-α, while polarization toward the M2 state occurs through the actions of interleukin (IL)-4 and IL-13. M2 macrophages also secrete the anti-inflammatory cytokine IL-10 and reduce the production of pro-inflammatory cytokines. A study suggested that lipocalin directly regulates the phenotype of macrophages and facilitates their transition from the pro-inflammatory M1 state to the anti-inflammatory M2 state (41). Furthermore, as shown in a model of collar-induced carotid atherosclerosis, adiponectin derived from PVAT has anti-atherosclerotic properties through its capacity to initiate Akt/FOXO3-dependent autophagy in macrophages (83).
3.2.2 UCP1
The mitochondrial inner membrane protein UCP1 is predominantly detected in BeAT/BAT and was originally recognized as a thermogenic protein responsible for eliminating excessive energy as heat. The gene expression patterns in the mouse thoracic PVAT are remarkably similar to the patterns in interscapular BAT (iBAT), and human coronary PVAT also shows expression of brown adipocyte-specific genes such as UCP1. Recent research has revealed that UCP1 has a protective role against vascular dysfunction and atherosclerosis by inhibiting the activation of Nod-like receptor family pyrin domain-containing 3(NLRP3) inflammatory vesicles in PVAT (84). This inhibition causes a reduction in NLRP3 inflammatory vesicles, which in turn decreases the levels of pro-inflammatory factors such as IL-1β (41). Notably, UCP1 deficiency did not alter the circulating or BAT levels of inflammatory factors. Furthermore, reintroduction of UCP1 in iBAT did not revert the increased atherosclerosis in UCP1-deficient mice, implying that the vascular regulation by UCP1 can be attributed, at least in part, to UCP1 in PVAT. Gu and colleagues conducted ex vivo research and showed that UCP1 in PVAT directly prevents endothelial dysfunction in intact aortic rings from mouse and porcine models (32). Through co-culture studies, they found that short-term processing of PVAT with BAM15 or co-expression with IL-1β-neutralizing antibodies improved endothelium-dependent PVAT relaxation in obese individuals. In conclusion, their study provides support for the notion that UCP1 partly exerts its vasculoprotective effects through its anti-inflammatory effects in PVAT.
3.2.3 Dendritic cell depletion
Previous research has demonstrated that the depletion of adipocytes expressing CD11c mRNA has a significant effect on reducing inflammatory responses in both obese visceral adipose tissue and the general circulation (85). In a murine model of type 2 diabetes mellitus (T2DM), dendritic cells predominantly accumulated in PVAT, rather than in the vessel wall itself. The buildup of dendritic cells in PVAT was related to the overproduction of proinflammatory cytokines, which in turn led to a decrease in the ability of PVAT to enhance vasodilatory and anticontractile activity in patients with T2DM. Recent investigations further indicated that depletion of dendritic cells considerably reduced the production of TNF-α and IL-6 in adipose tissue of a mouse model of type 2 diabetes, while simultaneously reducing the generation of IL-10 (38). In conclusion, depletion of dendritic cells dramatically reduces the generation of pro-inflammatory agents in diabetic PVAT, thereby attenuating chronic inflammation.
3.2.4 FGF-21
FGF-21 is a member of the fibroblast growth factor gene family that has a vital role as an endocrine regulator. Its primary functions include promotion of weight loss, regulation of insulin signaling, and control of glucose and lipid metabolism (86). FGF-21-induced glucose uptake and FGF-21 anti-inflammatory effects were shown to be mediated by separate signaling channels, and FGF-21 was further found to exhibit anti-inflammatory effects, particularly in adipocytes, that were facilitated by the fibroblast growth factor receptor substrate 2/ERK1/2 signaling pathway (48).
4 Relationship between PVAT and cardiovascular disease and the potential of PVAT as a therapeutic target
Table 3 summarizes the associations of PVAT with atherosclerosis, hypertension, and heart failure. We searched for potential therapeutic targets based on various aspects of the pathogenesis of these diseases as well as the cardioprotective effects of PVAT.
Table 3 Associations between PVAT and cardiovascular diseases.
4.1 PVAT and atherosclerosis
PVAT, which envelops blood vessels, was previously believed to be an inactive and unresponsive tissue. However, emerging evidence has strongly suggested that PVAT plays a critical role in regulating vascular function and contributes to the development of atherosclerosis (16, 31, 93–95). Atherosclerosis is a chronic and progressive metabolic disease characterized by buildup of lipids, dysfunction of the endothelium, and infiltration of inflammatory cells (96). The initial trigger for atherosclerosis is dysfunction or injury to the endothelium resulting from high shear stress, which induces adherence of inflammatory cells to the damaged endothelium and leads to cholesterol buildup within the arterial wall, facilitating the development of atherosclerosis (97, 98). These observations support the theory that atherosclerosis develops from the inside to the outside, because the adhesion of inflammatory cells to the dysfunctional endothelium triggers the accumulation of cholesterol in the artery wall (97). However, there is also evidence showing that PVAT, located in the outermost layer of the arterial wall, can contribute to the development of atherosclerosis through a different mechanism known as outside-to-inside pathogenesis (99). This outside-to-inside pathogenesis often occurs through disrupted endothelial function caused by impaired function of PVAT itself or changes in its function arising from variations in physical and chemical factors in the external environment. One study showed that thermogenic PVAT in the aorta was able to restore endothelial function in senescent mice (16). Activation of PVAT in the mice by mild cold treatment improved the endothelial function and prevented the occurrence of atherosclerosis. In contrast, mice deficient in PVAT exhibited serious atherosclerotic lesions that were not attenuated by mild cold irradiation. Furthermore, absence of PVAT led to increased infiltration of macrophages in the perivascular region of the aorta as well as increased generation of inflammatory cytokines, thereby inducing increased vascular inflammation and atherosclerotic plaque in the aortic lumen (16). Meanwhile, PVAT-induced inflammation and fibrosis may be part of the pathological process for arterial stiffness. A recent study demonstrated that secretion of mature IL-1β by macrophages is dependent on triggering the NLRP3 inflammasome, a member of the Nod-like receptor family (87). And this inflammasome is involved in an intracellular mechanism that acts through caspase-1 to mobilize the proinflammatory cytokines IL-1β and IL-18. Thus, owing to their distinctive functional and biochemical properties, it can be argued that perivascular adipocytes play an important role in the initiation of inflammation in atherosclerosis (26).
Numerous studies have demonstrated that adipokines derived from PVAT have a direct effect on the progression of atherosclerosis (100–103). A potential role for adipokines derived from subcutaneous adipocytes in atherosclerosis has also been suggested (40, 83).
Grafting of wild-type mouse thoracic PVAT to the carotid arteries of ApoE−/− mice significantly decreased the plaque macrophage content, without affecting plaque size (83). In contrast, transplantation of thoracic PVAT from ApoE−/− mice resulted in elevated amounts of inflammatory cytokines compared with transplantation of wild-type PVAT (104). In addition, melatonin was able to maintain the anti-contractile activity of PVAT and increase the expression of adiponectin and its receptors (105).
Another study demonstrated the anti-inflammatory effects of a cyclopentane triterpenoid called (16S,20S,24R)-12β-acetoxy-16,23-epoxy-24,25-dihydroxy-3β-(β-D-xylopyranosyloxy)-9,19-cyclolanost-22 (23)-ene (AEDC), derived from the buttercup family (Ranunculaceae). This compound showed promising results in the treatment of LPS-264.7 macrophages because it inhibited IL-1β generation and secretion. The underlying mechanism for the suppression involved SIRT3 autophagy-mediated inactivation of NLRP3 inflammatory vesicles and SIRT3-SOD2-mediated scavenging of reactive oxygen species (106). AEDC not only prevented inflammatory crosstalk between macrophages and adipocytes but also blocked the migration of macrophages to adipocytes. By mitigating macrophage accumulation, AEDC effectively alleviated adipose tissue inflammation. Therefore, there is a need to further develop AEDC as a potential drug of choice for the treatment of adipose tissue inflammation and related metabolic diseases.
4.2 PVAT and hypertension
Hypertension is a significant risk factor for various medical conditions, including stroke, aortic aneurysm, and coronary artery disease. It is characterized by a gradual increase in arterial blood pressure. Although contributing factors to hypertension include problems with the heart, kidneys, and nervous system, research has demonstrated that obesity also has a role in its development and progression. Existence of PVAT in obese individuals was found to reduce the contractile reaction of vascular rings. Nevertheless, this anti-contractile activity was markedly attenuated in obese individuals and obese mice (107). The pathogenesis of hypertension is complex and multifactorial, with various mechanisms by which adipose tissue could be involved in its development, particularly through variations in the secretion of adipokines. Adipocytes secrete numerous substances that affect vascular tone, and in obesity, their expression of vasodilators, such as lipocalin, NO, and H2S, is reduced. Adipose tissue also has its own RAAS, with angiotensinogen(Agt) being highly expressed in obese adipose tissue and potentially leading to renal dysfunction. Abnormal RAAS activation is crucial in the primary and later stages of hypertension. Elevated levels of Agt were observed in adipose tissue of rats suffering from primary hypertension and obesity, and the levels and capacities of Agt, plasma renin, and angiotensin-converting enzyme in the adipose tissue were directly correlated with obesity (89–91). These observations suggest that adipose tissue may be the main source for the RAAS in obese hypertensive patients (108). Locally, angiotensin II is derived from Agt, which is also present in PVAT. The entire vessel wall expresses four angiotensin receptors, and angiotensin type 1 receptor (AT1R) activation in PVAT enhances vascular inflammation and endothelial dysfunction (88).
Renin-angiotensin antagonists have been observed to maintain the anti-contractile function of perivascular tissues. In one study, researchers conducted in vitro hypoxic experiments that simulated the disinhibition of the anti-contractile function of PVAT in obese patients (109). Specifically, they contracted the tissue with increasing amounts of norepinephrine under normoxia or hypoxia and then incubated the tissue with captopril or telmisartan. Their findings showed that renin-angiotensin antagonists could effectively prevent the loss of the anti-contractile function of PVAT.
In addition, aldosterone may directly influence PVAT by promoting a proinflammatory phenotype. Angiotensin receptor blockers (ARBs) have potential as therapeutic targets by reducing the release of angiotensin II and aldosterone through the angiotensin-converting function of PVAT. ARBs also promote the generation of perivascular relaxing factors, which generate vasodilation by opening voltage-dependent K-channels on vascular ECs (110, 111). RAAS inhibition by ARBs and aldosterone inhibitors induces lower blood pressure and provides cardiovascular benefits, with effects that extend beyond the main target organs, such as the kidney and heart, to also affect PVAT (112).
SIRT3 has been identified as a regulator of glycolysis-dependent NLRP3 inflammatory vesicle activation, suggesting that SIRT3 may have potential as a therapeutic target for reducing PVAT inflammation. A recent study showed that bone marrow SIRT3 deficiency aggravated PVAT remodeling, leading to macrophage infiltration and adipose tissue dysfunction (84). Furthermore, NLRP3 deficiency protected macrophage function and prevented hypertension-induced inflammatory damage to PVAT.
4.3 PVAT and heart failure
Enhanced RAAS activation throughout the body, accompanied by heightened amounts of angiotensin II in the bloodstream, plays a crucial role in heart failure. Endothelial dysfunction, as a consequence of heart failure, is closely related to RAAS activation (113). A study even demonstrated a decrease in the anti-contractile effect of PVAT in the thoracic aorta of rats with heart failure (114). This reduction in the effect of PVAT may be attributed to the considerably decreased availability of NO. Existing literature indicates that decreased NO availability is a common occurrence in heart failure-induced endothelial dysfunction (92, 115). This reduced bioavailability of NO may arise through a decrease in its synthesis and/or an increase in its degradation by reactive oxygen species (92).
The above studies emphasize the potential contribution of PVAT to the pathophysiology of vascular dysfunction in heart failure and provide novel insights into the management of this disease. Thus, the use of RAAS inhibitors and the promotion of increased NO in patients with heart failure may be useful therapeutic strategies for the treatment of heart failure.
5 Discussion
Following the discovery of the anti-constrictive properties of PVAT in 1991, growing numbers of basic and clinical investigations have revealed important roles of PVAT in the cardiovascular system, its structural composition and cellular origins, and the release of various vasoactive molecules, thereby highlighting its essential effects on the cardiovascular system. Moreover, many studies have demonstrated its value as a possible therapeutic target from the viewpoint of its protective functions in the normal physiological state. Therefore, PVAT has potential as a candidate therapeutic target for restoring, delaying, and/or counteracting vascular dysfunction.
Author contributions
YT: Writing – original draft. ZZ: Writing – original draft. XL:Writing – original draft. ML: Software, Writing – original draft. ZW: Software, Writing – original draft. XG: Writing – original draft. XW: Writing – original draft. YS: Writing – original draft. ZGZ: Writing – review & editing. DC: Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Acknowledgments
The authors thank Alison Sherwin, PhD, from Liwen Bianji (Edanz) (www.liwenbianji.cn/) for editing the English text of a draft of this manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J (2017) 38(32):2459–72. doi: 10.1093/eurheartj/ehx144
2. Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb (2018) 25(9):846–984. doi: 10.5551/jat.GL2017
3. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, et al. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res (2006) 71(2):363–73. doi: 10.1016/j.cardiores.2006.03.013
4. Eringa EC, Bakker W, van Hinsbergh VW. Paracrine regulation of vascular tone, inflammation and insulin sensitivity by perivascular adipose tissue. Vascul Pharmacol (2012) 56(5-6):204–9. doi: 10.1016/j.vph.2012.02.003
5. Aghamohammadzadeh R, Withers S, Lynch F, Greenstein A, Malik R, Heagerty A. Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol (2012) 165(3):670–82. doi: 10.1111/j.1476-5381.2011.01479.x
6. Bjørndal B, Burri L, Staalesen V, Skorve J, Berge RK. Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J Obes (2011) 2011:490650. doi: 10.1155/2011/490650
7. Szasz T, Webb RC. Perivascular adipose tissue: more than just structural support. Clin Sci (Lond) (2012) 122(1):1–12. doi: 10.1042/cs20110151
8. Fernández-Alfonso MS, Gil-Ortega M, Aranguez I, Souza D, Dreifaldt M, Somoza B, et al. Role of PVAT in coronary atherosclerosis and vein graft patency: friend or foe? Br J Pharmacol (2017) 174(20):3561–72. doi: 10.1111/bph.13734
9. Angueira AR, Sakers AP, Holman CD, Cheng L, Arbocco MN, Shamsi F, et al. Defining the lineage of thermogenic perivascular adipose tissue. Nat Metab (2021) 3(4):469–84. doi: 10.1038/s42255-021-00380-0
10. Takaoka M, Suzuki H, Shioda S, Sekikawa K, Saito Y, Nagai R, et al. Endovascular injury induces rapid phenotypic changes in perivascular adipose tissue. Arterioscler Thromb Vasc Biol (2010) 30(8):1576–82. doi: 10.1161/atvbaha.110.207175
11. Gollasch M. Vasodilator signals from perivascular adipose tissue. Br J Pharmacol (2012) 165(3):633–42. doi: 10.1111/j.1476-5381.2011.01430.x
12. Lin G, Garcia M, Ning H, Banie L, Guo YL, Lue TF, et al. Defining stem and progenitor cells within adipose tissue. Stem Cells Dev (2008) 17(6):1053–63. doi: 10.1089/scd.2008.0117
13. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 112(12):1796–808. doi: 10.1172/jci19246
14. Kumar RK, Jin Y, Watts SW, Rockwell CE. Naïve, regulatory, activated, and memory immune cells co-exist in PVATs that are comparable in density to non-PVAT fats in health. Front Physiol (2020) 11:58. doi: 10.3389/fphys.2020.00058
15. Kvetnansky R, Ukropec J, Laukova M, Manz B, Pacak K, Vargovic P. Stress stimulates production of catecholamines in rat adipocytes. Cell Mol Neurobiol (2012) 32(5):801–13. doi: 10.1007/s10571-012-9822-6
16. Chang L, Villacorta L, Li R, Hamblin M, Xu W, Dou C, et al. Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-γ deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation (2012) 126(9):1067–78. doi: 10.1161/circulationaha.112.104489
17. Fraser JK, Schreiber R, Strem B, Zhu M, Alfonso Z, Wulur I, et al. Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes. Nat Clin Pract Cardiovasc Med (2006) 3 Suppl:1, S33–7. doi: 10.1038/ncpcardio0444
18. Berti L, Hartwig S, Irmler M, Rädle B, Siegel-Axel D, Beckers J, et al. Impact of fibroblast growth factor 21 on the secretome of human perivascular preadipocytes and adipocytes: a targeted proteomics approach. Arch Physiol Biochem (2016) 122(5):281–8. doi: 10.1080/13813455.2016.1212898
19. Gu W, Nowak WN, Xie Y, Le Bras A, Hu Y, Deng J, et al. Single-cell RNA-sequencing and metabolomics analyses reveal the contribution of perivascular adipose tissue stem cells to vascular remodeling. Arterioscler Thromb Vasc Biol (2019) 39(10):2049–66. doi: 10.1161/atvbaha.119.312732
20. Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol (2012) 165(3):643–58. doi: 10.1111/j.1476-5381.2011.01404.x
21. Gao YJ. Dual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/lipoatrophy-related vascular dysfunction. Curr Pharm Des (2007) 13(21):2185–92. doi: 10.2174/138161207781039634
22. Cinti S. Between brown and white: novel aspects of adipocyte differentiation. Ann Med (2011) 43(2):104–15. doi: 10.3109/07853890.2010.535557
23. Morigny P, Boucher J, Arner P, Langin D. Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics. Nat Rev Endocrinol (2021) 17(5):276–95. doi: 10.1038/s41574-021-00471-8
24. Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: a mini-review. Gerontology (2012) 58(1):15–23. doi: 10.1159/000321319
25. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med (2009) 360(15):1509–17. doi: 10.1056/NEJMoa0810780
26. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res (2009) 104(4):541–9. doi: 10.1161/circresaha.108.182998
27. Padilla J, Jenkins NT, Vieira-Potter VJ, Laughlin MH. Divergent phenotype of rat thoracic and abdominal perivascular adipose tissues. Am J Physiol Regul Integr Comp Physiol (2013) 304(7):R543–52. doi: 10.1152/ajpregu.00567.2012
28. Police SB, Thatcher SE, Charnigo R, Daugherty A, Cassis LA. Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol (2009) 29(10):1458–64. doi: 10.1161/atvbaha.109.192658
29. Gálvez-Prieto B, Bolbrinker J, Stucchi P, de Las Heras AI, Merino B, Arribas S, et al. Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J Endocrinol (2008) 197(1):55–64. doi: 10.1677/joe-07-0284
30. Efremova A, Senzacqua M, Venema W, Isakov E, Di Vincenzo A, Zingaretti MC, et al. A large proportion of mediastinal and perirenal visceral fat of Siberian adult people is formed by UCP1 immunoreactive multilocular and paucilocular adipocytes. J Physiol Biochem (2020) 76(2):185–92. doi: 10.1007/s13105-019-00721-4
31. Fitzgibbons TP, Kogan S, Aouadi M, Hendricks GM, Straubhaar J, Czech MP. Similarity of mouse perivascular and brown adipose tissues and their resistance to diet-induced inflammation. Am J Physiol Heart Circ Physiol 301(4) H1425-37 (2011). doi: 10.1152/ajpheart.00376.2011
32. Gu P, Hui X, Zheng Q, Gao Y, Jin L, Jiang W, et al. Mitochondrial uncoupling protein 1 antagonizes atherosclerosis by blocking NLRP3 inflammasome-dependent interleukin-1β production. Sci Adv 7(50) eabl4024 (2021). doi: 10.1126/sciadv.abl4024
33. Zhang J, Zhong W, Cui T, Yang M, Hu X, Xu K, et al. Generation of an adult smooth muscle cell-targeted Cre recombinase mouse model. Arterioscler Thromb Vasc Biol (2006) 26(3):e23–4. doi: 10.1161/01.Atv.0000202661.61837.93
34. Chang L, Villacorta L, Zhang J, Garcia-Barrio MT, Yang K, Hamblin M, et al. Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation (2009) 119(16):2161–9. doi: 10.1161/circulationaha.108.815803
35. Robinson S. Physiological effects of heat and cold. Annu Rev Physiol (1952) 14:73–96. doi: 10.1146/annurev.ph.14.030152.000445
36. Hu H, Garcia-Barrio M, Jiang ZS, Chen YE, Chang L. Roles of perivascular adipose tissue in hypertension and atherosclerosis. Antioxid Redox Signal (2021) 34(9):736–49. doi: 10.1089/ars.2020.8103
37. Gálvez-Prieto B, Somoza B, Gil-Ortega M, García-Prieto CF, de Las Heras AI, González MC, et al. Anticontractile effect of perivascular adipose tissue and leptin are reduced in hypertension. Front Pharmacol (2012) 3:103. doi: 10.3389/fphar.2012.00103
38. Qiu T, Li M, Tanner MA, Yang Y, Sowers JR, Korthuis RJ, et al. Depletion of dendritic cells in perivascular adipose tissue improves arterial relaxation responses in type 2 diabetic mice. Metabolism (2018) 85:76–89. doi: 10.1016/j.metabol.2018.03.002
39. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem (2003) 278(45):45021–6. doi: 10.1074/jbc.M307878200
40. Margaritis M, Antonopoulos AS, Digby J, Lee R, Reilly S, Coutinho P, et al. Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation (2013) 127(22):2209–21. doi: 10.1161/circulationaha.112.001133
41. Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem (2010) 285(9):6153–60. doi: 10.1074/jbc.M109.088708
42. Montfort WR, Wales JA, Weichsel A. Structure and activation of soluble guanylyl cyclase, the nitric oxide sensor. Antioxid Redox Signal (2017) 26(3):107–21. doi: 10.1089/ars.2016.6693
43. Wang R. Shared signaling pathways among gasotransmitters. Proc Natl Acad Sci U.S.A. (2012) 109(23):8801–2. doi: 10.1073/pnas.1206646109
44. Fang L, Zhao J, Chen Y, Ma T, Xu G, Tang C, et al. Hydrogen sulfide derived from periadventitial adipose tissue is a vasodilator. J Hypertens (2009) 27(11):2174–85. doi: 10.1097/HJH.0b013e328330a900
45. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C, et al. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler Thromb Vasc Biol (2010) 30(10):1998–2004. doi: 10.1161/atvbaha.110.209783
46. Mendizábal Y, Llorens S, Nava E. Vasoactive effects of prostaglandins from the perivascular fat of mesenteric resistance arteries in WKY and SHROB rats. Life Sci (2013) 93(25-26):1023–32. doi: 10.1016/j.lfs.2013.10.021
47. Lee RM, Bader M, Alenina N, Santos RA, Gao YJ, Lu C. Mas receptors in modulating relaxation induced by perivascular adipose tissue. Life Sci (2011) 89(13-14):467–72. doi: 10.1016/j.lfs.2011.07.016
48. Wang N, Zhao TT, Li SM, Sun X, Li ZC, Li YH, et al. Fibroblast growth factor 21 exerts its anti-inflammatory effects on multiple cell types of adipose tissue in obesity. Obes (Silver Spring) (2019) 27(3):399–408. doi: 10.1002/oby.22376
49. Bełtowski J. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin Exp Pharmacol Physiol (2012) 39(2):168–78. doi: 10.1111/j.1440-1681.2011.05623.x
50. Jamroz-Wiśniewska A, Gertler A, Solomon G, Wood ME, Whiteman M, Bełtowski J. Leptin-induced endothelium-dependent vasorelaxation of peripheral arteries in lean and obese rats: role of nitric oxide and hydrogen sulfide. PloS One (2014) 9(1):e86744. doi: 10.1371/journal.pone.0086744
51. Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, Surwit RS. Role of leptin in fat regulation. Nature (1996) 380(6576):677. doi: 10.1038/380677a0
52. Xia N, Horke S, Habermeier A, Closs EI, Reifenberg G, Gericke A, et al. Uncoupling of endothelial nitric oxide synthase in perivascular adipose tissue of diet-induced obese mice. Arterioscler Thromb Vasc Biol (2016) 36(1):78–85. doi: 10.1161/atvbaha.115.306263
53. Weston AH, Egner I, Dong Y, Porter EL, Heagerty AM, Edwards G. Stimulated release of a hyperpolarizing factor (ADHF) from mesenteric artery perivascular adipose tissue: involvement of myocyte BKCa channels and adiponectin. Br J Pharmacol (2013) 169(7):1500–9. doi: 10.1111/bph.12157
54. Almabrouk TAM, Ugusman AB, Katwan OJ, Salt IP, Kennedy S. Deletion of AMPKα1 attenuates the anticontractile effect of perivascular adipose tissue (PVAT) and reduces adiponectin release. Br J Pharmacol (2017) 174(20):3398–410. doi: 10.1111/bph.13633
55. Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiology–emerging clinical applications. Nat Clin Pract Endocrinol Metab (2006) 2(6):318–27. doi: 10.1038/ncpendmet0196
56. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d’Amati G, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes (2000) 49(2):293–7. doi: 10.2337/diabetes.49.2.293
57. Vecchione C, Maffei A, Colella S, Aretini A, Poulet R, Frati G, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes (2002) 51(1):168–73. doi: 10.2337/diabetes.51.1.168
58. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest (1997) 100(9):2146–52. doi: 10.1172/jci119750
59. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J (2012) 33(7):829–37. doi: 10.1093/eurheartj/ehr304
60. Dashwood MR, Dooley A, Shi-Wen X, Abraham DJ, Souza DS. Does periadventitial fat-derived nitric oxide play a role in improved saphenous vein graft patency in patients undergoing coronary artery bypass surgery? J Vasc Res (2007) 44(3):175–81. doi: 10.1159/000099833
61. Gil-Ortega M, Stucchi P, Guzmán-Ruiz R, Cano V, Arribas S, González MC, et al. Adaptative nitric oxide overproduction in perivascular adipose tissue during early diet-induced obesity. Endocrinology (2010) 151(7):3299–306. doi: 10.1210/en.2009-1464
62. Virdis A, Duranti E, Rossi C, Dell’Agnello U, Santini E, Anselmino M, et al. Tumour necrosis factor-alpha participates on the endothelin-1/nitric oxide imbalance in small arteries from obese patients: role of perivascular adipose tissue. Eur Heart J (2015) 36(13):784–94. doi: 10.1093/eurheartj/ehu072
63. Yuan XJ, Tod ML, Rubin LJ, Blaustein MP. NO hyperpolarizes pulmonary artery smooth muscle cells and decreases the intracellular Ca2+ concentration by activating voltage-gated K+ channels. Proc Natl Acad Sci U.S.A. (1996) 93(19):10489–94. doi: 10.1073/pnas.93.19.10489
64. Liew HC, Khoo HE, Moore PK, Bhatia M, Lu J, Moochhala SM. Synergism between hydrogen sulfide (H(2)S) and nitric oxide (NO) in vasorelaxation induced by stonustoxin (SNTX), a lethal and hypotensive protein factor isolated from stonefish Synanceja horrida venom. Life Sci (2007) 80(18):1664–8. doi: 10.1016/j.lfs.2007.01.058
65. Lee SW, Cheng Y, Moore PK, Bian JS. Hydrogen sulphide regulates intracellular pH in vascular smooth muscle cells. Biochem Biophys Res Commun (2007) 358(4):1142–7. doi: 10.1016/j.bbrc.2007.05.063
66. Li L, Rose P, Moore PK. Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol (2011) 51:169–87. doi: 10.1146/annurev-pharmtox-010510-100505
67. Nagpure BV, Bian JS. Interaction of hydrogen sulfide with nitric oxide in the cardiovascular system. Oxid Med Cell Longev (2016) 2016:6904327. doi: 10.1155/2016/6904327
68. Lei YP, Liu CT, Sheen LY, Chen HW, Lii CK. Diallyl disulfide and diallyl trisulfide protect endothelial nitric oxide synthase against damage by oxidized low-density lipoprotein. Mol Nutr Food Res (2010) 54 Suppl:1, S42–52. doi: 10.1002/mnfr.200900278
69. Yong QC, Lee SW, Foo CS, Neo KL, Chen X, Bian JS. Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning. Am J Physiol Heart Circ Physiol (2008) 295(3):H1330–h1340. doi: 10.1152/ajpheart.00244.2008
70. Coletta C, Papapetropoulos A, Erdelyi K, Olah G, Módis K, Panopoulos P, et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci U.S.A. (2012) 109(23):9161–6. doi: 10.1073/pnas.1202916109
71. Sojitra B, Bulani Y, Putcha UK, Kanwal A, Gupta P, Kuncha M, et al. Nitric oxide synthase inhibition abrogates hydrogen sulfide-induced cardioprotection in mice. Mol Cell Biochem (2012) 360(1-2):61–9. doi: 10.1007/s11010-011-1044-6
72. Ardanaz N, Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med (Maywood) (2006) 231(3):237–51. doi: 10.1177/153537020623100302
73. Santiago E, Martínez MP, Climent B, Muñoz M, Briones AM, Salaices M, et al. Augmented oxidative stress and preserved vasoconstriction induced by hydrogen peroxide in coronary arteries in obesity: role of COX-2. Br J Pharmacol (2016) 173(22):3176–95. doi: 10.1111/bph.13579
74. Costa RM, Filgueira FP, Tostes RC, Carvalho MH, Akamine EH, Lobato NS. H2O2 generated from mitochondrial electron transport chain in thoracic perivascular adipose tissue is crucial for modulation of vascular smooth muscle contraction. Vascul Pharmacol (2016) 84:28–37. doi: 10.1016/j.vph.2016.05.008
75. Félétou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol (2006) 291(3):H985–1002. doi: 10.1152/ajpheart.00292.2006
76. Meyer MR, Fredette NC, Barton M, Prossnitz ER. Regulation of vascular smooth muscle tone by adipose-derived contracting factor. PloS One (2013) 8(11):e79245. doi: 10.1371/journal.pone.0079245
77. Xia N, Li H. The role of perivascular adipose tissue in obesity-induced vascular dysfunction. Br J Pharmacol (2017) 174(20):3425–42. doi: 10.1111/bph.13650
78. Lee RM, Lu C, Su LY, Gao YJ. Endothelium-dependent relaxation factor released by perivascular adipose tissue. J Hypertens (2009) 27(4):782–90. doi: 10.1097/HJH.0b013e328324ed86
79. Lee YC, Chang HH, Chiang CL, Liu CH, Yeh JI, Chen MF, et al. Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension. Circulation (2011) 124(10):1160–71. doi: 10.1161/circulationaha.111.027375
80. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation (2002) 106(22):2767–70. doi: 10.1161/01.cir.0000042707.50032.19
81. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol (2015) 12(1):10–7. doi: 10.1038/nrcardio.2014.173
82. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun (2004) 323(2):630–5. doi: 10.1016/j.bbrc.2004.08.145
83. Li C, Wang Z, Wang C, Ma Q, Zhao Y. Perivascular adipose tissue-derived adiponectin inhibits collar-induced carotid atherosclerosis by promoting macrophage autophagy. PloS One (2015) 10(5):e0124031. doi: 10.1371/journal.pone.0124031
84. Wei T, Gao J, Huang C, Song B, Sun M, Shen W. SIRT3 (Sirtuin-3) prevents ang II (Angiotensin II)-induced macrophage metabolic switch improving perivascular adipose tissue function. Arterioscler Thromb Vasc Biol (2021) 41(2):714–30. doi: 10.1161/atvbaha.120.315337
85. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab (2008) 8(4):301–9. doi: 10.1016/j.cmet.2008.08.015
86. Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol (2016) 78:223–41. doi: 10.1146/annurev-physiol-021115-105339
87. Liu P, Xie Q, Wei T, Chen Y, Chen H, Shen W. Activation of the NLRP3 inflammasome induces vascular dysfunction in obese OLETF rats. Biochem Biophys Res Commun (2015) 468(1-2):319–25. doi: 10.1016/j.bbrc.2015.10.105
88. Sakaue T, Suzuki J, Hamaguchi M, Suehiro C, Tanino A, Nagao T, et al. Perivascular adipose tissue angiotensin II type 1 receptor promotes vascular inflammation and aneurysm formation. Hypertension (2017) 70(4):780–9. doi: 10.1161/hypertensionaha.117.09512
89. Müller-Fielitz H, Lau M, Jöhren O, Stellmacher F, Schwaninger M, Raasch W. Blood pressure response to angiotensin II is enhanced in obese Zucker rats and is attributed to an aldosterone-dependent mechanism. Br J Pharmacol (2012) 166(8):2417–29. doi: 10.1111/j.1476-5381.2012.01953.x
90. Dinh Cat AN, Friederich-Persson M, White A, Touyz RM. Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol 57(1) F7-f21 (2016). doi: 10.1530/jme-16-0025
91. Yiannikouris F, Gupte M, Putnam K, Thatcher S, Charnigo R, Rateri DL, et al. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension (2012) 60(6):1524–30. doi: 10.1161/hypertensionaha.112.192690
92. Couto GK, Paula SM, Gomes-Santos IL, Negrão CE, Rossoni LV. Exercise training induces eNOS coupling and restores relaxation in coronary arteries of heart failure rats. Am J Physiol Heart Circ Physiol (2018) 314(4):H878–h887. doi: 10.1152/ajpheart.00624.2017
93. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol (2015) 11(6):363–71. doi: 10.1038/nrendo.2015.58
94. Kawahito H, Yamada H, Irie D, Kato T, Akakabe Y, Kishida S, et al. Periaortic adipose tissue-specific activation of the renin-angiotensin system contributes to atherosclerosis development in uninephrectomized apoE-/- mice. Am J Physiol Heart Circ Physiol (2013) 305(5):H667–75. doi: 10.1152/ajpheart.00053.2013
95. Fitzgibbons TP, Czech MP. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J Am Heart Assoc (2014) 3(2):e000582. doi: 10.1161/jaha.113.000582
96. Singh RB, Mengi SA, Xu YJ, Arneja AS, Dhalla NS. Pathogenesis of atherosclerosis: A multifactorial process. Exp Clin Cardiol (2002) 7(1):40–53.
97. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart (2006) 92(4):441–4. doi: 10.1136/hrt.2005.066936
98. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol (2004) 24(1):12–22. doi: 10.1161/01.ATV.0000105054.43931.f0
99. Wilcox JN, Scott NA. Potential role of the adventitia in arteritis and atherosclerosis. Int J Cardiol (1996) 54 Suppl:S21–35. doi: 10.1016/s0167-5273(96)02811-2
100. Lynch FM, Withers SB, Yao Z, Werner ME, Edwards G, Weston AH, et al. Perivascular adipose tissue-derived adiponectin activates BK(Ca) channels to induce anticontractile responses. Am J Physiol Heart Circ Physiol (2013) 304(6):H786–95. doi: 10.1152/ajpheart.00697.2012
101. Li H, Wang YP, Zhang LN, Tian G. Perivascular adipose tissue-derived leptin promotes vascular smooth muscle cell phenotypic switching via p38 mitogen-activated protein kinase in metabolic syndrome rats. Exp Biol Med (Maywood) (2014) 239(8):954–65. doi: 10.1177/1535370214527903
102. Soehnlein O, Drechsler M, Döring Y, Lievens D, Hartwig H, Kemmerich K, et al. Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med (2013) 5(3):471–81. doi: 10.1002/emmm.201201717
103. Park SY, Kim KH, Seo KW, Bae JU, Kim YH, Lee SJ, et al. Resistin derived from diabetic perivascular adipose tissue up-regulates vascular expression of osteopontin via the AP-1 signalling pathway. J Pathol (2014) 232(1):87–97. doi: 10.1002/path.4286
104. Ren L, Wang L, You T, Liu Y, Wu F, Zhu L, et al. Perivascular adipose tissue modulates carotid plaque formation induced by disturbed flow in mice. J Vasc Surg (2019) 70(3):927–936.e4. doi: 10.1016/j.jvs.2018.09.064
105. Agabiti-Rosei C, De Ciuceis C, Rossini C, Porteri E, Rodella LF, Withers SB, et al. Anticontractile activity of perivascular fat in obese mice and the effect of long-term treatment with melatonin. J Hypertens (2014) 32(6):1264–74. doi: 10.1097/hjh.0000000000000178
106. Zhang T, Fang Z, Linghu KG, Liu J, Gan L, Lin L. Small molecule-driven SIRT3-autophagy-mediated NLRP3 inflammasome inhibition ameliorates inflammatory crosstalk between macrophages and adipocytes. Br J Pharmacol (2020) 177(20):4645–65. doi: 10.1111/bph.15215
107. Hong CH, Kuo TB, Huang BC, Lin YC, Kuo KL, Chern CM, et al. Cold exposure can induce an exaggerated early-morning blood pressure surge in young prehypertensives. PloS One (2016) 11(2):e0150136. doi: 10.1371/journal.pone.0150136
108. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med (2003) 157(8):821–7. doi: 10.1001/archpedi.157.8.821
109. Rosei CA, Withers SB, Belcaid L, De Ciuceis C, Rizzoni D, Heagerty AM. Blockade of the renin-angiotensin system in small arteries and anticontractile function of perivascular adipose tissue. J OF HYPERTENSION (2015) 33(5):1039–45. doi: 10.1097/HJH.0000000000000506
110. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension (2012) 59(5):1069–78. doi: 10.1161/hypertensionaha.111.190223
111. Kagota S, Maruyama-Fumoto K, Shimari M, McGuire JJ, Shinozuka K. Angiotensin II type 1 receptor antagonist azilsartan restores vascular reactivity through a perivascular adipose tissue-independent mechanism in rats with metabolic syndrome. Cardiovasc Drugs Ther (2019) 33(5):501–9. doi: 10.1007/s10557-019-06900-1
112. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 160(6):1273–92. doi: 10.1111/j.1476-5381.2010.00750.x
113. dos Santos L, Gonçalves MV, Vassallo DV, Oliveira EM, Rossoni LV. Effects of high sodium intake diet on the vascular reactivity to phenylephrine on rat isolated caudal and renal vascular beds: Endothelial modulation. Life Sci (2006) 78(19):2272–9. doi: 10.1016/j.lfs.2005.09.028
114. Fontes MT, Paula SM, Lino CA, Senger N, Couto GK, Barreto-Chaves MLM, et al. Renin-angiotensin system overactivation in perivascular adipose tissue contributes to vascular dysfunction in heart failure. Clin Sci (Lond) (2020) 134(23):3195–211. doi: 10.1042/cs20201099
Keywords: perivascular adipose tissue, anti-inflammatory, vasodilatory, anticontractile, hypertension, atherosclerosis
Citation: Tong Y, Zuo Z, Li X, Li M, Wang Z, Guo X, Wang X, Sun Y, Chen D and Zhang Z (2023) Protective role of perivascular adipose tissue in the cardiovascular system. Front. Endocrinol. 14:1296778. doi: 10.3389/fendo.2023.1296778
Received: 19 September 2023; Accepted: 27 November 2023;
Published: 08 December 2023.
Edited by:
Say Viengchareun, Institut National de la Santé et de la Recherche Médicale (INSERM), FranceReviewed by:
Jacqueline Beaudry, University of Toronto, CanadaIldiko Szanto, Hôpitaux universitaires de Genève (HUG), Switzerland
Copyright © 2023 Tong, Zuo, Li, Li, Wang, Guo, Wang, Sun, Chen and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhiguo Zhang, emhhbmd6aGlnQGpsdS5lZHUuY24=; Dongmei Chen, Y2hlbmRtMTk4OEAxMjYuY29t
†These authors have contributed equally to this work